Clinical Trial Update: A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. [Phase 2]

View source ↗

Summary

Phase 2 trial of AZD4635 combined with durvalumab, and with cabazitaxel + durvalumab, in progressive metastatic castration-resistant prostate cancer has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• AZD4635 (AZD4635)
• Cabazitaxel (cabazitaxel)
• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Progressive Metastatic Castrate-Resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-08-09